Status:
UNKNOWN
Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Merck Frosst Canada Ltd.
Conditions:
Glaucoma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic nerve perfusion. ...
Detailed Description
High intraocular pressure (IOP) is the major risk factor for glaucoma. Lowering intraocular pressure is still the only accepted form of treatment for glaucoma. Over the past decade, epidemiological a...
Eligibility Criteria
Inclusion
- Males or females 20-80 years of age.
- Presence of typical early glaucomatous optic disc changes (cup/disc ratio ≤ 0.75) and/or early glaucomatous visual field defects (mean deviation less than 5dB and outside of 10° from fixation) in the study eye at the baseline visit.
- Best corrected visual acuity of at least 20/40.
- Signed informed consent from the subject
- The subject should be able to understand the instructions and perform the HRF and CLBF tests as well as be willing and able to comply with the study schedule and treatment.
Exclusion
- Pregnant women or nursing mothers.
- Any other active ocular disease (ocular infections, Uveitis, etc.)
- Known allergy or sensitivity to the study medications.
- Functionally significant visual field loss (mean deviation greater than 5dB) or cup/disc ratio greater than 0.75 or evidence of progressive visual field loss within the last 6 months.
- Required chronic use of other ocular or systemic hypotensive medications during the study, other than the study medication (e.g. beta-blockers, Ca-channel blockers)
- Vascular occlusive disease affecting the ocular circulation such as: diabetic retinopathy, central retinal vein occlusion, central retinal artery occlusion, or non-arteritic ischemic optic neuropathy.
- Previous intraocular surgery or ocular traumas.
- Any past history of serious systemic condition affecting cerebral circulation including: hypertension, diabetes, cerebral vascular accident (CVA), or coronary artery bypass graft (CABG).
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2006
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00152932
Start Date
May 1 2005
End Date
June 1 2006
Last Update
July 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology and Visual Sciences; Toronto Western Hospital
Toronto, Ontario, Canada